By itself, use of electronic health records (EHRs) does not improve the quality of care for heart failure, says Mary Norine Walsh, MD.
By itself, use of electronic health records (EHRs) does not improve the quality of care for heart failure, says Mary Norine Walsh, MD.
In a national study, outpatient cardiology practices that used EHRs performed no better on six of seven care measures than those that did not use EHRs.
Seven quality-of-care measures were compared between 87 sites that used electronic health records (50 used them exclusively, 37 used a combination of electronic and paper records) and 80 sites that used paper records only. The seven measures were all evidence-based guideline-recommended practices:
Only the use of aldosterone-receptor blockers in appropriate patients and the provision of heart failure education were significantly more common among the sites that used EHRs compared with the sites that did not. When adjusted for practice characteristics, only the provision of heart failure education remained significantly better among the sites that adopted electronic records.
“These observations are consistent with a recent 2008 Health Information Technology in the United States [study] that found no significant association between electronic health record use and quality of care,” says Dr. Walsh, a cardiologist and director of nuclear cardiology and congestive heart failure at St. Vincent Hospital in Indianapolis. Performance improvement interventions may also be needed in addition to electronic records to influence quality of care and clinical outcomes, she adds.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More